ReviewWorld journal of gastroenterology2012
Human endogenous retroviruses and cancer: causality and therapeutic possibilities.
Review in World journal of gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- Survey of gene, lncRNA and transposon transcription patterns in four mouse organs highlights shared and organ-specific sex-biased regulation.Genome biology · 2025Article
- HERVs and Cancer-A Comprehensive Review of the Relationship of Human Endogenous Retroviruses and Human Cancers.Biomedicines · 2023Review
- Human Endogenous Retroviruses as Gene Expression Regulators: Insights from Animal Models into Human Diseases.Molecules and cells · 2021Review
- Dynamic LTR retrotransposon transcriptome landscape in septic shock patients.Critical care (London, England) · 2020Article
- Extracellular Vesicles Released by Colorectal Cancer Cell Lines Modulate Innate Immune Response in Zebrafish Model: The Possible Role of Human Endogenous Retroviruses.International journal of molecular sciences · 2019Article
- HERV Envelope Proteins: Physiological Role and Pathogenic Potential in Cancer and Autoimmunity.Frontiers in microbiology · 2018Review
- Downregulation of Human Endogenous Retrovirus Type K (HERV-K) ViralClinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Age-related reduction of antibody response against the human endogenous retrovirus K envelope in women.Oncotarget · 2016Article
- Expression of evolutionarily novel genes in tumors.Infectious agents and cancer · 2016Review
- Generation, Characterization and Application of Antibodies Directed against HERV-H Gag Protein in Colorectal Samples.PloS one · 2016Article
- Insight into the ERVK Integrase - Propensity for DNA Damage.Frontiers in microbiology · 2016Article
- Expression of young HERV-H loci in the course of colorectal carcinoma and correlation with molecular subtypes.Oncotarget · 2015Article
- Human endogenous retrovirus K and cancer: Innocent bystander or tumorigenic accomplice?International journal of cancer · 2015Review
- The saga of XMRV: a virus that infects human cells but is not a human virus.Emerging microbes & infections · 2014Review
- Microarray-based identification of individual HERV loci expression: application to biomarker discovery in prostate cancer.Journal of visualized experiments : JoVE · 2013Article
- HERV-K(HML-2), the Best Preserved Family of HERVs: Endogenization, Expression, and Implications in Health and Disease.Frontiers in oncology · 2013Review
- Frequency of human endogenous retroviral sequences (HERV) K113 and K115 in the Polish population, and their effect on HIV infection.PloS one · 2013Article
- Expression of human endogenous retrovirus-w including syncytin-1 in cutaneous T-cell lymphoma.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A substantial part of the human genome is derived from transposable elements; remnants of ancient retroviral infections. Conservative estimates set the percentage of human endogenous retroviruses (HERVs) in the genome at 8%. For the most part, the interplay between mutations, epigenetic mechanisms and posttranscriptional regulations silence HERVs in somatic cells. We first highlight mechanisms by which activation of members of several HERV families may be associated with tumor development before discussing the arising chances for both diagnosis and therapy. It has been shown that at least in some cases, tumor cells expressing HERV open reading frames (ORFs) thus gain tumor-promoting functions. However, since these proteins are not expressed in healthy tissues, they become prime target structures. Of potential pharmacological interest are the prevention of HERV transposition, the inhibition of HERV-encoded protein expression and the interference with these proteins' activities. Evidence from recent studies unequivocally proves that HERV ORFs represent a very interesting source of novel tumor-specific antigens with even the potential to surpass entity boundaries. The development of new tumor (immune-) therapies is a very active field and true tumor-specific targets are of outstanding interest since they minimize the risk of autoimmunity and could reduce side effects. Finally, we postulate on main future research streams in order to stimulate discussion on this hot topic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.